Glomerular disorder
MONDO:0019722A disease involving the renal glomerulus.
Also known as: disease of renal glomerulus, disease or disorder of renal glomerulus, disorder of renal glomerulus, glomerulopathy, renal glomerulus disease, renal glomerulus disease or disorder, glomerulopathies
416 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Personalized interferon therapy aims to tame kidney disease without weakening defenses
Disease control TerminatedThis phase 2 trial investigates whether a personalized course of peginterferon alfa-2a can control membranous nephropathy, an autoimmune kidney disease. The treatment targets the Th17 inflammatory pathway, which is linked to a higher risk of relapse. Participants receive injectio…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control TerminatedThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising vasculitis drug trial halted early
Disease control TerminatedThis study compared two drugs, obinutuzumab and rituximab, for treating a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal was to see if obinutuzumab could help more patients achieve remission and clear disease markers. However, the trial…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Hydroxychloroquine trial for rare vasculitis halted early
Disease control TerminatedThis study tested whether hydroxychloroquine, a drug used for lupus and arthritis, could help control ANCA vasculitis—a group of autoimmune diseases that cause blood vessel inflammation. Adults with mild disease activity were randomly assigned to receive hydroxychloroquine or a p…
Phase: PHASE4 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug OMS721 tested for rare kidney conditions
Disease control TerminatedThis study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Kidney disease drug trial halted early after only 6 patients
Disease control TerminatedThis early-stage study tested a new drug called VB119 in 6 adults with primary membranous nephropathy, a kidney disease. The main goal was to check safety and how the body handles the drug, not to cure the disease. The study was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Tenet Medicines • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Lupus kidney drug for teens shows promise, but trial cut short
Disease control TerminatedThis study tested a drug called voclosporin in teenagers with lupus nephritis, a kidney disease caused by lupus. The goal was to see if it could improve kidney function better than a placebo. Only 9 teens took part before the study was stopped early, so we don't have clear answer…
Phase: PHASE3 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lupus kidney drug tested in kids – but study stopped early
Disease control TerminatedThis study looked at the long-term safety of the drug voclosporin in adolescents and children with lupus nephritis, a kidney disease caused by lupus. Participants took voclosporin capsules twice daily along with standard medications. The trial was terminated early and only enroll…
Phase: PHASE3 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control TerminatedThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental drug ravulizumab tested for kidney inflammation
Disease control TerminatedThis Phase 2 study tested the drug ravulizumab (Ultomiris) in 123 adults with lupus nephritis or IgA nephropathy, two conditions that cause kidney inflammation. Participants received either ravulizumab or a placebo alongside standard care. The study aimed to see if the drug could…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Kidney disease drug combo shows promise in small trial
Disease control TerminatedThis study looked at whether adding cyclosporine to rituximab is more effective than rituximab alone for treating idiopathic membranous nephropathy, a kidney disease that causes protein leakage. Only 12 adults with severe proteinuria took part before the study ended early. The go…
Phase: PHASE3 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Kidney disease drug trial halted midway
Disease control TerminatedThis study tested a drug called OMS721 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. The trial was stopped early, so results are limited.
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Lupus kidney drug trial halted midway
Disease control TerminatedThis study tested a drug called zetomipzomib for people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could improve kidney function better than a placebo over 52 weeks. The trial was terminated early, so results are limited. Partic…
Phase: PHASE2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Kidney disease drug trial halted midway: what happened?
Disease control TerminatedThis study tested a drug called ALXN2050 in people with kidney inflammation caused by lupus (lupus nephritis) or IgA nephropathy. The goal was to see if it could reduce protein in the urine, a sign of kidney damage. About 100 adults were planned to take the drug or a placebo alon…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Blood test may help some ANCA patients skip unnecessary drugs
Knowledge-focused TerminatedThis study looked at whether a specific type of immune cell (CD5+ regulatory B cells) can predict relapse risk in people with ANCA vasculitis, a rare autoimmune disease that damages blood vessels. Researchers aimed to see if patients with normal levels of these cells after initia…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC